Morgan Stanley’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $504M | Buy |
44,693,966
+8,767,207
| +24% | +$98.8M | 0.03% | 495 |
|
|
2025
Q1 | $363M | Buy |
35,926,759
+1,311,686
| +4% | +$13.2M | 0.03% | 584 |
|
|
2024
Q4 | $409M | Buy |
34,615,073
+4,941,069
| +17% | +$58.5M | 0.03% | 543 |
|
|
2024
Q3 | $342M | Buy |
29,674,004
+343,865
| +1% | +$3.97M | 0.02% | 603 |
|
|
2024
Q2 | $310M | Sell |
29,330,139
-6,305,362
| -18% | -$66.6M | 0.02% | 616 |
|
|
2024
Q1 | $376M | Sell |
35,635,501
-8,218,587
| -19% | -$86.6M | 0.03% | 547 |
|
|
2023
Q4 | $492M | Buy |
43,854,088
+24,542,457
| +127% | +$276M | 0.02% | 686 |
|
|
2023
Q3 | $226M | Buy |
19,311,631
+6,324,915
| +49% | +$73.9M | 0.02% | 646 |
|
|
2023
Q2 | $131M | Buy |
12,986,716
+9,810,452
| +309% | +$98.9M | 0.01% | 928 |
|
|
2023
Q1 | $23.4M | Buy |
3,176,264
+2,831,760
| +822% | +$20.9M | ﹤0.01% | 2249 |
|
|
2022
Q4 | $2.75M | Buy |
344,504
+303,340
| +737% | +$2.42M | ﹤0.01% | 4244 |
|
|
2022
Q3 | $132K | Buy |
41,164
+14,982
| +57% | +$48K | ﹤0.01% | 5936 |
|
|
2022
Q2 | $106K | Buy |
26,182
+25,869
| +8,265% | +$105K | ﹤0.01% | 6243 |
|
|
2022
Q1 | $2K | Sell |
313
-427
| -58% | -$2.73K | ﹤0.01% | 7755 |
|
|
2021
Q4 | $7K | Buy |
+740
| New | +$7K | ﹤0.01% | 7575 |
|